Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting
March 27, 2019 08:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, M.D., March 27, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient...
Rexahn Pharmaceuticals Reports 2018 Financial Results
March 08, 2019 08:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., March 08, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient...
Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE® in First-line Metastatic Pancreatic Cancer Patients
March 04, 2019 08:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., March 04, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient...
Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors
March 01, 2019 08:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., March 01, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient...
Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium
February 19, 2019 08:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient...
Rexahn Announces Presentations at the 2019 ASCO Genitourinary Cancers Symposium
February 06, 2019 08:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient...
Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types
February 04, 2019 08:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient...
Rexahn Announces Pricing of Public Offering of Common Stock and Warrants
January 23, 2019 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) today announced the pricing of an underwritten public offering of 10,750,000 shares of its common...
Rexahn Announces Proposed Public Offering of Common Stock and Warrants
January 22, 2019 16:42 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) today announced that it intends to offer and sell shares of its common stock and warrants to...
Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium
January 22, 2019 07:30 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient...